



## Summary of Changes Report – January 2009

# Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD)

---

### Algorithm

The algorithm was revised: Box #1 is Establish a Diagnosis of COPD. This was formerly Box #3. Signs and Symptoms of COPD are included in Box #1. Another box was added to include smoking cessation discussion and support. The annotation verbiage for Box #12 is included in Box #11, Pharmacologic approach for managing COPD. Box #14 Assess for hypoxemia and hypercapnia and the annotation verbiage was eliminated.

### Clinical Highlights

Some of the clinical highlights were deleted or revised. Two were added: Tobacco cessation is the only known intervention that can slow progression of lung function loss; and, pulmonary rehabilitation is beneficial for all COPD patients in all stages.

An **Introduction** about COPD was added.

### Annotations

- \*1) An explanation of alpha 1-anti-trypsin was added to determining the diagnosis of COPD. (*Stroller, 2003*)
- \*3) A table of smoking cessation products was added.
- \*6) The verbiage for Steroid therapy for acute exacerbations was updated. (*Aaron, 2003; Thompson 1996*)
- \*11) Table II chart/diagram of therapy at each level/stage of severity of COPD was updated. This information is from the *GOLD 2008* guideline.
- \*11) The section on systemic and inhaled corticosteroids was revised. (*Pauwells,1999; Calverly, 2007*)
- \*11) Metered dose inhalers may use hydrofluro-alkane (HFA) as the propellant. A directory of types of HFAs was added as Appendix B. Also Table III was revised to include HFAs.
- \*11) The section on Theophylline was revised.
- \*11) The section on antiviral agents was updated. Zanamivir is no longer recommended for patients with COPD. (*Fiore, 2008*)
- \*12) The section on pulmonary rehabilitation was revised. (*DiMeo, 2008; Berry, 1999*)
- \*12) The section on COPD and air travel was updated.

### Appendices

Appendix A, Daily Dosages for Inhaled Corticosteroids was revised.  
Appendix B is now a directory of HFA propellants.

### Priority Aims & Suggested Measures, Measurement Specifications

Aim and measures #6 were deleted.

*\*An asterisk indicates any changes in clinical practice recommendations*